Pfizer Moving Ahead With Polymerase Inhibitors For Hep C As Competitors Fall
This article was originally published in The Pink Sheet Daily
Executive Summary
Activity and tolerability profile of the Phase IIa compound encourage Pfizer to proceed with development.